NMRA Jumps 46% as Healthcare Small Caps Lead EPS Revision Rally
Neumora Therapeutics (NMRA) surged 46.1% to $0.57 after its next-year EPS growth estimate was revised up 1.1 percentage points on October 29, leading a broad rally in EPS-revision small caps. Cosmos Health (COSM) gained 30.4% following a 14.8-point upward revision, while Replimune (REPL) rose 28.6% after beating Q2 estimates and launching its melanoma therapy TUDRIQEV. Vertiv (VRT) added 18.1% on a blowout quarter and fourth guidance raise.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| NMRA | Healthcare | 2026-10-29 | +1.1pp | +46.1% |
| COSM | Healthcare | 2026-10-26 | +14.8pp | +30.4% |
| REPL | Healthcare | 2026-10-28 | +1.4pp | +28.6% |
| XLO | Healthcare | 2026-10-26 | N/A | +18.7% |
| VRT | Industrials | 2026-10-26 | N/A | +18.1% |
Why did NMRA stock jump in November 2026?
NMRA jumped 46.1% (from $0.39 to $0.57) after analysts raised its next-year EPS growth estimate from 30.1% to 31.1% on October 29.
The micro-cap biotech's tiny float amplified the move, with no company-specific news in the window; the repricing reflects a sector-wide bid for beaten-down healthcare names with improving earnings trajectories. The screener flagged the revision early, and the subsequent price action confirmed that even a modest estimate uptick can unlock outsized gains in low-priced, thinly traded equities.
NMRA EPS revision history → · Screener snapshot from 2026-10-29 →
FAQ: NMRA
Why did NMRA stock jump in October 2026?
NMRA jumped 46.1% from $0.39 to $0.57 after its next-year EPS growth estimate was revised up from 30.1% to 31.1% on October 29, 2026. The move was amplified by the stock's low price and thin liquidity.
Is NMRA a buy after the rally?
NMRA remains a speculative micro-cap with no revenue and no company-specific news driving the gain. The 46% rally was purely estimate-driven, so investors should weigh the lack of fundamental catalysts against the improved EPS outlook.
What is NMRA's EPS growth estimate?
NMRA's next-year EPS growth estimate is 31.1% as of November 3, 2026, up from 30.1% before the October 29 revision.
Why did COSM stock jump in November 2026?
COSM surged 30.4% (from $0.23 to $0.30) after its next-year EPS growth estimate was revised from 131.8% to 146.7% on October 26.
The 14.8-percentage-point upward revision is the largest in this cohort, signaling a sharp improvement in expected profitability for the healthcare distributor. With no earnings-related news in the window, the gain appears driven by the revision itself in a low-float, low-priced stock where small estimate changes translate into large percentage moves.
COSM EPS revision history → · Screener snapshot from 2026-10-26 →
FAQ: COSM
Why did COSM stock jump in October 2026?
COSM jumped 30.4% from $0.23 to $0.30 after its next-year EPS growth estimate was revised from 131.8% to 146.7% on October 26, 2026. The 14.8-point upward revision was the largest among the stocks in this screen.
What caused COSM's surge?
The surge was driven by a sharp upward revision to its forward EPS growth estimate, with no company-specific news in the window. Low liquidity amplified the price impact of the estimate change.
What is COSM's EPS growth estimate?
COSM's next-year EPS growth estimate is 146.7% as of November 3, 2026, up from 131.8% before the October 26 revision.
Why did REPL stock jump in November 2026?
REPL rose 28.6% (from $16.06 to $20.65) after its next-year EPS growth estimate was revised from 33.9% to 35.3% on October 28, the same day it reported a fiscal Q2 loss of $0.54 per share that beat the $0.70 consensus by 22.9%.
The beat came from lower R&D spending as trials wound down, but the real catalyst was the commercial launch of TUDRIQEV for advanced melanoma, with more than 15 institutions having prescribed the therapy since its October 6 availability. The estimate revision and the launch news together reframed REPL as a revenue-stage story, and the market repriced accordingly.
REPL EPS revision history → · Screener snapshot from 2026-10-28 →
FAQ: REPL
Why did REPL stock jump in October 2026?
REPL jumped 28.6% from $16.06 to $20.65 after its next-year EPS growth estimate was revised from 33.9% to 35.3% on October 28, 2026. The revision coincided with a Q2 earnings beat and the commercial launch of TUDRIQEV.
Is REPL a buy after the rally?
REPL's investment case now hinges on the TUDRIQEV launch, with more than 15 institutions prescribing the $450,000-per-course therapy. The Q2 beat was driven by cost cuts, not revenue, so execution on the launch will determine whether the rally sustains.
What caused REPL's surge?
REPL's surge was caused by a double catalyst: an upward EPS estimate revision and the first commercial availability of TUDRIQEV for advanced melanoma, which shifted the company from pre-revenue to launch stage.
Why did XLO stock jump in November 2026?
XLO climbed 18.7% (from $7.31 to $8.68) after its next-year EPS growth estimate was set at 31.1% on October 26, with no earnings-related news in the window.
The oncology biotech's gain reflects broader sector momentum, as investors rotated into small-cap healthcare names with positive earnings revisions. The screener caught the estimate early, and the steady price appreciation suggests accumulation rather than a single-event spike.
XLO EPS revision history → · Screener snapshot from 2026-10-26 →
FAQ: XLO
Why did XLO stock jump in October 2026?
XLO jumped 18.7% from $7.31 to $8.68 after its next-year EPS growth estimate was set at 31.1% on October 26, 2026. No company-specific news was found in the window, so the move reflects sector-wide rotation into small-cap healthcare.
Is XLO a buy after the rally?
XLO's 18.7% gain came without company-specific news, so the rally may be vulnerable to reversal if sector momentum fades. The 31.1% EPS growth estimate provides fundamental support, but caution is warranted given the lack of catalysts.
What is XLO's EPS growth estimate?
XLO's next-year EPS growth estimate is 31.1% as of November 3, 2026, unchanged since the October 26 detection.
Why did VRT stock jump in November 2026?
VRT jumped 18.1% (from $199.78 to $235.97) after its next-year EPS growth estimate was set at 36.8% on October 26, ahead of a Q3 blowout that sent shares up 14% on October 28.
The data center infrastructure firm reported adjusted EPS of $2.21, beating the $1.82 consensus by 16.3%, on revenue of $4.31 billion that topped estimates by 14.7%. Management raised full-year 2026 guidance to $7.10-$7.20 in EPS on revenue of $14.45-$14.85 billion, citing accelerating AI infrastructure demand. The stock had been priced for trouble after a 15.2% three-month decline, so the estimate revision and subsequent beat collided with pessimistic positioning to produce a sharp reversal.
VRT EPS revision history → · Screener snapshot from 2026-10-26 →
FAQ: VRT
Why did VRT stock jump in October 2026?
VRT jumped 18.1% from $199.78 to $235.97 after its next-year EPS growth estimate was set at 36.8% on October 26, followed by a Q3 beat on October 28 that included a fourth guidance raise. The stock had been down 15.2% over the prior three months, amplifying the reversal.
Is VRT a buy after the rally?
VRT raised its 2026 EPS guidance to $7.10-$7.20, above the $6.74 consensus, on accelerating AI data center demand. The stock remains nearly 40% below its May 2026 record high, leaving room for further re-rating if the infrastructure buildout continues.
What caused VRT's surge?
VRT's surge was caused by a blowout Q3 with adjusted EPS of $2.21 beating the $1.82 consensus, revenue up 61% to $4.31 billion, and a fourth full-year guidance raise. The results validated the earlier EPS estimate revision.
Today's performers show that EPS estimate revisions—even modest ones—can still drive outsized gains in small-cap healthcare when positioning is light, while VRT's blowout quarter proves that estimate upgrades in large-cap industrials can force sharp reversals from overly pessimistic sentiment.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →